These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25240757)

  • 1. Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines.
    Ward BJ; Landry N; Trépanier S; Mercier G; Dargis M; Couture M; D'Aoust MA; Vézina LP
    Vaccine; 2014 Oct; 32(46):6098-106. PubMed ID: 25240757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro.
    Hendin HE; Pillet S; Lara AN; Wu CY; Charland N; Landry N; Ward BJ
    Vaccine; 2017 May; 35(19):2592-2599. PubMed ID: 28389100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens.
    Landry N; Pillet S; Favre D; Poulin JF; Trépanier S; Yassine-Diab B; Ward BJ
    Clin Immunol; 2014 Oct; 154(2):164-77. PubMed ID: 25128897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.
    Le Mauff F; Mercier G; Chan P; Burel C; Vaudry D; Bardor M; Vézina LP; Couture M; Lerouge P; Landry N
    Plant Biotechnol J; 2015 Jun; 13(5):717-25. PubMed ID: 25523794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza.
    Landry N; Ward BJ; Trépanier S; Montomoli E; Dargis M; Lapini G; Vézina LP
    PLoS One; 2010 Dec; 5(12):e15559. PubMed ID: 21203523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response.
    Hodgins B; Yam KK; Winter K; Pillet S; Landry N; Ward BJ
    Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of H1N1 influenza virus-like particles produced in Nicotiana benthamiana.
    Shoji Y; Prokhnevsky A; Leffet B; Vetter N; Tottey S; Satinover S; Musiychuk K; Shamloul M; Norikane J; Jones RM; Chichester JA; Green BJ; Streatfield SJ; Yusibov V
    Hum Vaccin Immunother; 2015; 11(1):118-23. PubMed ID: 25483524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural rubber latex and hymenoptera venoms share ImmunoglobinE-epitopes accounting for cross-reactive carbohydrate determinants.
    Mahler V; Gutgesell C; Valenta R; Fuchs T
    Clin Exp Allergy; 2006 Nov; 36(11):1446-56. PubMed ID: 17083355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults.
    Pillet S; Aubin É; Trépanier S; Bussière D; Dargis M; Poulin JF; Yassine-Diab B; Ward BJ; Landry N
    Clin Immunol; 2016 Jul; 168():72-87. PubMed ID: 26987887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin-E reactivity to a glycosylated food allergen (peanuts) due to interference with cross-reactive carbohydrate determinants in heavy drinkers.
    Vidal C; Vizcaino L; Díaz-Peromingo JA; Garrido M; Gomez-Rial J; Linneberg A; Gonzalez-Quintela A
    Alcohol Clin Exp Res; 2009 Aug; 33(8):1322-8. PubMed ID: 19413651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages.
    Makarkov AI; Chierzi S; Pillet S; Murai KK; Landry N; Ward BJ
    Vaccine; 2017 Aug; 35(35 Pt B):4629-4636. PubMed ID: 28712489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy.
    Lindsay BJ; Bonar MM; Costas-Cancelas IN; Hunt K; Makarkov AI; Chierzi S; Krawczyk CM; Landry N; Ward BJ; Rouiller I
    Vaccine; 2018 Apr; 36(16):2147-2154. PubMed ID: 29550194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and characterization of a trackable plant-made influenza H5 virus-like particle (VLP) containing enhanced green fluorescent protein (eGFP).
    Young KR; Arthus-Cartier G; Yam KK; Lavoie PO; Landry N; D'Aoust MA; Vézina LP; Couture MM; Ward BJ
    FASEB J; 2015 Sep; 29(9):3817-27. PubMed ID: 26038124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin-E reactivity to wine glycoproteins in heavy drinkers.
    Gonzalez-Quintela A; Gomez-Rial J; Valcarcel C; Campos J; Sanz ML; Linneberg A; Gude F; Vidal C
    Alcohol; 2011 Mar; 45(2):113-22. PubMed ID: 20843643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
    Low JG; Lee LS; Ooi EE; Ethirajulu K; Yeo P; Matter A; Connolly JE; Skibinski DA; Saudan P; Bachmann M; Hanson BJ; Lu Q; Maurer-Stroh S; Lim S; Novotny-Diermayr V
    Vaccine; 2014 Sep; 32(39):5041-8. PubMed ID: 25045806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
    D'Aoust MA; Lavoie PO; Couture MM; Trépanier S; Guay JM; Dargis M; Mongrand S; Landry N; Ward BJ; Vézina LP
    Plant Biotechnol J; 2008 Dec; 6(9):930-40. PubMed ID: 19076615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG2 dominancy and carbohydrate recognition specificity of C3H/He mouse antibodies directed to cross-reactive carbohydrate determinants (CCDs) bearing beta-(1,2)-xylose and alpha-(1,3)-fucose.
    Hino S; Umeda F; Inumaru S; Aoki N; Sato C; Okajima T; Nadano D; Matsuda T
    Immunol Lett; 2010 Sep; 133(1):28-34. PubMed ID: 20600324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Affinity of IgE and IgG against cross-reactive carbohydrate determinants on plant and insect glycoproteins.
    Jin C; Hantusch B; Hemmer W; Stadlmann J; Altmann F
    J Allergy Clin Immunol; 2008 Jan; 121(1):185-190.e2. PubMed ID: 17881041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.